Close Menu

NEW YORK – Agilent Technologies reported after the close of the market on Monday that its fiscal fourth quarter revenues rose 6 percent year over year, thanks largely to an 8 percent increase in revenues for its crosslab unit and a 5 percent increase in revenues in its diagnostics and genomics business.

For the three months ended Oct. 31, the firm said revenues rose to $1.37 billion from $1.29 billion in Q4 2018, beating the average Wall Street estimate of $1.33 billion. The company said core revenues grew 4 percent year over year in Q4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.